# US 2025/0152618 A1 · Antiviral sulfated chitosan derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152618 A1
- Document ID: US20250152618A1
- Status: Published application
- Kind: A1
- Application number: 18/838,844
- Filed: 2023-02-13
- Published: 2025-05-15
- Earliest claimed: 2022-02-15
- Assignees: Consejo Superior De Investigaciones Cientificas (Csic); Universitat De Valencia
- Applicants: Consejo Superior De Investigaciones Cientificas (Csic); Universitat De ValèNcia
- Inventors: Alfonso FERNÁNDEZ-MAYORALAS ÁLVAREZ; Julia REVUELTA CRESPO; Eduardo GARCÍA-JUNCEDA REDONDO; Agatha BASTIDA CODINA; Ron GELLER; Clara FRANCÉS GÓMEZ; Victor LATORRE ROSELLÓ; Miguel Ángel MARTÍN ACEBES; Juan Carlos SAIZ CALAHORRA; Alfonso GUTIÉRREZ ADÁN
- Web page: https://patentgrep.com/patent/US20250152618A1

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61P 31/14: for RNA viruses
- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.

## Claims

### Claim 1

A compound of formula I:
wherein:
each of R1, R2 or R3 independently represents H or —SO3M; with the proviso that total sulfation degree of compound expressed by Z is of between 0.05 and 3, and wherein Z is calculated in base to elemental analysis of compound according to this general formula: Z=(S%/32.06)/(N%/14.01); wherein S% and N% represent the percentage of each element by weight
M represents an alkali metal cation selected from Na+, K+, Cs+ or Li+; R4 represents —CO—(CH2)7—CH═CH—(CH2)7—CH3;
m represents from 0 to 1760 repeating units;
n represents from 1 to 1100 repeating units; and
o represents from 1 to 2100 repeating units.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein M is Na+.

### Claim 3 (depends on 1)

The compound according to claim 1, selected from:
m=1-5, n=1-5, o=5-40, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-5-L15-O-1.6);
m=0, n=1-5, o=9-35, R1=SO3−Na+ H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=2.5 (CHIT-5-N,O-2.5);
m=0, n=1-5, o=9-35, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=0.5-2.0 (CHIT-5-O-1.8);
m=10-20, n=5-15; o=55-95, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-15-L15-O-1.6);
m=20-35, n=5-15, o=40-70, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.7 (CHIT-15-L30-O-1.7);
m=40-70, n=5-15, o=20-35, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-15-L50-O-1.6);
m=10-20, n=5-15; o=55-95, R1=SO3−Na+ H, R2=R3=H, Z=0.7 (CHIT-15-L15-N-0.7);
m=0, n=5-15, o=65-105, R1=SO3−Na+ H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=2.0 (CHIT-15-N,O-2.0);
m=0, n=5-15, o=65-105, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-15-O-1.6);
m=0, n=5-15, o=65-105, R1=SO3−Na+ H, R2=R3=H, Z=0.7 (CHIT-15-N-0.7);
m=7-30, n=5-20, o=45-125, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.7 (CHIT-20-L15-O-1.7);
m=15-35, n=15-40, o=75-160, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.7 (CHIT-30-L15-O-1.7);
m=33-54, n=33-54, o=154-252, R1=H, R2=R3=SO3−Na+ H, Z=1.6 (CHIT-50-L15-O-1.6)
m=69-90, n=92-120, o=299-390, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.7 (CHIT-90-L15-O-1.7);
m=105-173, n=105-173, o=490-806, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-125-L15-O-1.6).

### Claim 4 (depends on 1)

The compound according to claim 1, selected from:
m=10-20, n=5-15; o=55-95, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-15-L15-O-1.6);
m=20-35, n=5-15, o=40-70, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-15-L30-O-1.7);
m=0, n=5-15, o=65-105, R1=SO3−Na+ H, R2=R3=H, Z=0.7 (CHIT-15-N-0.7);
m=0, n=5-15, o=65-105, R1=SO3−Na+ H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=2.0 (CHIT-15-N,O-2.0);
m=0, n=5-15, o=65-105, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-15-O-1.6);
m=15-35, n=15-40, o=75-160, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.7 (CHIT-30-L15-O-1.7); and
m=33-54, n=33-54, o=154-252, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-50-L15-O-1.6).

### Claim 5 (depends on 1)

The compound according to claim 1, selected from:
m=10-20, n=5-15, o=55-95, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ or H, Z=1.7 (CHIT-L15-O-1.6);
m=20-35, n=5-15, o=40-70, R1=H, R2=SO3−N+ or H, R3=SO3−Na+ or H, Z=1.6 (CHIT-15-L30-O-1.7);
m=15-35, n=15-40, o=75-160, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.7 (CHIT-30-L15-O-1.7); and
m=33-54, n=33-54, o=154-252, R1=H, R2=SO3−Na+ H, R3=SO3−Na+ H, Z=1.6 (CHIT-50-L15-O-1.6).

### Claim 6 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising a compound of formula I according to any of claims 1 to 5 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable vehicle, and optionally another active substance.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A compound of formula I according to any of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in therapy.

### Claim 8

A compound of formula II:
or a pharmaceutically acceptable salt thereof, wherein:
each of R1, R2 or R3 independently represents H or −SO3M; with the proviso that total sulfation degree of compound expressed by Z is of between 0.05 and 3, and wherein Z is calculated in base to elemental analysis of compound according to this general formula: Z= (S%/32.06)/(N%/14.01); wherein S % and N % represent the percentage of each element by weight
M represents a monovalent cation, preferably pyridinium cation, an ammonium cation or an alkali metal cation;
R4 represents —CO—(CH2)7—CH═CH—(CH2)7—CH3;
m represents from 0 to 1760 repeating units;
n represents from 1 to 1100 repeating units; and
o represents from 1 to 2100 repeating units,
for use in the treatment and/or prevention of a viral infections.

### Claim 9 (depends on 8)

The compound of formula II for the use according to claim 8 or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by SARS-CoV-2, respiratory syncytial virus (RSV), SARS-CoV-1, MERS, human Metapneumovirus (hMPV), Ebola Virus (EBOV), Herpes Simplex Virus (HSV), Human papillomavirus (HPV) and Dengue Virus (DENV).

### Claim 10 (depends on 9)

The compound of formula II for the use according to claim 9 or a pharmaceutically acceptable salt thereof, wherein the viral infection is caused by SARS-CoV-2 or respiratory syncytial virus (RSV).
